138 related articles for article (PubMed ID: 32671780)
21. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
22. A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Yeh YA; Pappas AA; Flick JT; Butch AW
Ann Clin Lab Sci; 2000 Jul; 30(3):283-8. PubMed ID: 10945569
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.
Grab AL; Seckinger A; Horn P; Hose D; Cavalcanti-Adam EA
Acta Biomater; 2019 Sep; 96():258-270. PubMed ID: 31302300
[TBL] [Abstract][Full Text] [Related]
24. Cold PSM, but not TRAIL, triggers autophagic cell death: A therapeutic advantage of PSM over TRAIL.
Ito T; Ando T; Suzuki-Karasaki M; Tokunaga T; Yoshida Y; Ochiai T; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2018 Aug; 53(2):503-514. PubMed ID: 29845256
[TBL] [Abstract][Full Text] [Related]
25. [Research Progress on Regulating Autophagy in the Treatment of Multiple Myeloma --Review].
Yang BQ; Chen JM; Zeng ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):700-703. PubMed ID: 32319420
[TBL] [Abstract][Full Text] [Related]
26. LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma.
Gao D; Lv AE; Li HP; Han DH; Zhang YP
J Cell Biochem; 2017 Oct; 118(10):3341-3348. PubMed ID: 28295550
[TBL] [Abstract][Full Text] [Related]
27. Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.
Al-Odat OS; Guirguis DA; Schmalbach NK; Yao G; Budak-Alpdogan T; Jonnalagadda SC; Pandey MK
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614089
[TBL] [Abstract][Full Text] [Related]
28. Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients.
Gadó K; Nagy G; Hasitz A; Tóth BE; Rimanóczi E; Domján G
Neuroimmunomodulation; 2001; 9(2):95-102. PubMed ID: 11549891
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma biology: lessons from the 5TMM models.
Vanderkerken K; Asosingh K; Croucher P; Van Camp B
Immunol Rev; 2003 Aug; 194():196-206. PubMed ID: 12846816
[TBL] [Abstract][Full Text] [Related]
30. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
31. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
Palacios C; Martín-Pérez R; López-Pérez AI; Pandiella A; López-Rivas A
Leuk Res; 2010 Nov; 34(11):1533-8. PubMed ID: 20667592
[TBL] [Abstract][Full Text] [Related]
32. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
[TBL] [Abstract][Full Text] [Related]
33. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.
Pan Y; Gao Y; Chen L; Gao G; Dong H; Yang Y; Dong B; Chen X
Clin Cancer Res; 2011 May; 17(10):3248-58. PubMed ID: 21288924
[TBL] [Abstract][Full Text] [Related]
34. The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.
Dotterweich J; Tower RJ; Brandl A; Müller M; Hofbauer LC; Beilhack A; Ebert R; Glüer CC; Tiwari S; Schütze N; Jakob F
PLoS One; 2016; 11(5):e0155087. PubMed ID: 27158817
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of immunomodulatory drugs in multiple myeloma.
Sedlarikova L; Kubiczkova L; Sevcikova S; Hajek R
Leuk Res; 2012 Oct; 36(10):1218-24. PubMed ID: 22727252
[TBL] [Abstract][Full Text] [Related]
36. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
37. The role of bone morphogenetic proteins in myeloma cell survival.
Holien T; Sundan A
Cytokine Growth Factor Rev; 2014 Jun; 25(3):343-50. PubMed ID: 24853340
[TBL] [Abstract][Full Text] [Related]
38. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
39. Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy.
Deighan WI; O'Kane MJ; McNicholl FP; Keren DF
Ann Clin Biochem; 2016 Nov; 53(6):706-711. PubMed ID: 27166317
[TBL] [Abstract][Full Text] [Related]
40. Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells.
Li M; Cortez S; Nakamachi T; Batuman V; Arimura A
Cancer Res; 2006 Sep; 66(17):8796-803. PubMed ID: 16951196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
